FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2025/06/089643 [Registered on: 26/06/2025] Trial Registered Prospectively
Last Modified On: 20/08/2025
Post Graduate Thesis  No 
Type of Trial  Interventional 
Type of Study   Diagnostic 
Study Design  Single Arm Study 
Public Title of Study   Assessment of sentinel lymph node biopsy procedure for detecting lymph node spread in women diagnosed with cervical cancer. 
Scientific Title of Study   Diagnostic performance of sentinel lymphnode biopsy algorithm in cervical cancer 
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Rohini Kulkarni 
Designation  Principal Investigator  
Affiliation  Tata Memorial Hospital 
Address  Room No. 54 Ground floor Homi Bhabha Block Dr Ernest Borges Marg Parel East Mumbai MAHARASHTRA 400012 India

Mumbai (Suburban)
MAHARASHTRA
400012
India 
Phone  8281376824  
Fax    
Email  dr.rohini.vk@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Rohini Kulkarni 
Designation  Principal Investigator  
Affiliation  Tata Memorial Hospital 
Address  Room No. 54 Ground floor Homi Bhabha Block Dr Ernest Borges Marg Parel East Mumbai MAHARASHTRA 400012 India

Mumbai (Suburban)
MAHARASHTRA
400012
India 
Phone  8281376824  
Fax    
Email  dr.rohini.vk@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Dr Manisha Choudhary 
Designation  Research Fellow Medical 
Affiliation  Tata Memorial Hospital 
Address  Room No. 54 Ground floor Homi Bhabha Block Dr Ernest Borges Marg Parel East Mumbai MAHARASHTRA 400012 India

Mumbai (Suburban)
MAHARASHTRA
400012
India 
Phone  7977370528  
Fax    
Email  manishachoudhary9004@gmail.com  
 
Source of Monetary or Material Support  
Tata Memorial Center 
 
Primary Sponsor  
Name  Tata Memorial Center 
Address  Tata Memorial Hospital Dr E BORGES ROAD PAREL MUMBAI 400012 
Type of Sponsor  Research institution and hospital 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Rohini Kulkarni  Tata Memorial Hospital  Gynaec OPD Tata Memorial Hospital Dr E BORGES ROAD PAREL MUMBAI 400012
Mumbai (Suburban)
MAHARASHTRA 
8281376824

dr.rohini.vk@gmail.com 
 
Details of Ethics Committee
Modification(s)  
No of Ethics Committees= 2  
Name of Committee  Approval Status 
Institutional Ethics Committee Tata Memorial Centre  Approved 
Institutional Ethics Committee Tata Memorial Centre  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: C539||Malignant neoplasm of cervix uteri, unspecified,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  NIL  NIL 
Comparator Agent  NIL  NIL 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  80.00 Year(s)
Gender  Female 
Details  1. To evaluate the SLN detection rates (DR)
i.Patient specific
ii.Side specific
iii.Bilateral
2. To calculate the sensitivity (Sn), false negative rate (FNR) and negative predictive value (NPV) of SLNM algorithm.
 
 
ExclusionCriteria 
Details  1. Inability to understand and/or consent for the procedure
2. ECOG 2 or more
3. Locally advanced disease/ enlarged or suspicious lymphnodes/ intrabdominal / distant metastasis on preoperative clinical assessment/ Ultrasonography/ CECT/ MRI pelvis/ chest X ray.
• Locally advanced disease detected intra operatively(bladder/ lateral parametrial/ uterosacral involvement/ intra peritoneal metastasis)
• Previous surgeries / procedures impairing lymphatic drainage (myomectomy/ retroperitoneal surgery/ abdominopelvic radiotherapy)
• Previous neo-adjuvant therapy – chemotherapy/ radiotherapy.
• Allergy to iodine
• Known liver disease
• Pre-existing lymphoedema.
 
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Not Applicable 
Blinding/Masking   Not Applicable 
Primary Outcome  
Outcome  TimePoints 
1. To evaluate the SLN detection rates (DR)
i. Patient specific
ii. Side specific
iii. Bilateral
2. To calculate the sensitivity (Sn), false negative rate (FNR) and negative predictive value (NPV) of SLNM algorithm.
 
after enrollment is completed  
 
Secondary Outcome  
Outcome  TimePoints 
- To calculate the sensitivity (Sn), false negative rate (FNR) and negative predictive value (NPV) of sentinel lymph node biopsy (SLNB).
- To calculate the sensitivity (Sn), false negative rate (FNR) and negative predictive value (NPV) of frozen section analysis (FSA) of SLNs.
- To assess intra operative adverse events related to the procedure.
 
after enrollment is completed  
 
Target Sample Size   Total Sample Size="20"
Sample Size from India="20" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   N/A 
Date of First Enrollment (India)   07/07/2025 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="6"
Days="0" 
Recruitment Status of Trial (Global)
Modification(s)  
Not Applicable 
Recruitment Status of Trial (India)  Open to Recruitment 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

Cervical cancer is a major contributor of cancer burden in India with an incidence of 1,27,526 new cases detected in 2022 and 79,906 deaths.

Only 20% of early stage cervical cancer patients have been found to have positive lymph nodes and the rest receive morbid procedure of systematic lymphadenectomy without any therapeutic benefit. The lymphnode positive patients are candidates for adjuvant concurrent chemoradiation (CCRT) and have to face the associated toxicity of dual modality treatment.

SLNB procedure has been evaluated in cervical cancers in various retrospective studies, few prospective studies and meta-analyses.

One of the first validation studies was SENTICOL, which showed very good sensitivity of 92%, Negative predictive value of 98.2%, bilateral detection rate of 76.5% . Subsequently, the most recent meta-analysis by Zhang et al showed a pooled side specific sensitivity of 88% . These outstanding results were obtained despite the use of traditional blue dye with radiocolloid and without ultrastaging. The debate regarding the choice of the dye has been put to rest by the FILM study, which has undeniably pointed towards the superiority of ICG.

TThe quality of life issues and onocological safety have been addressed in the subsequent SENTICOL 2 study. Lymphatic morbidity was significantly lower in the SLN arm (31.4%) compared to the SLN + PLND arm (51.5%; p = 0.0046), as was the rate of postoperative neurological symptoms (7.8% vs. 20.6%, p = 0.01, respectively(Mathevet Patrice). It demonstrated no significant difference in disease free survival (89.5 & 93.1%) or overall survival (95.2 & 96%) between the two groups as a secondary end point.  SENTICOL 3 is a large ongoing study investigating the same aspect .

Unlike endometrial carcinoma, intraoperative detection of lymphnode metastasis plays a major role in carcinoma cervix. Landmark study by Landoni et al advocated to avoid dual modality treatment due to increased morbidity without added survival benefit. Hence, lymphnodes if found positive on intra operative frozen section analysis(FSA), results in termination of the surgical procedure, and definitive concurrent chemoradiation.

The SENTIX trial has assessed the role of FSA on sentinel lymphnodes. They have reported a sensitivity of 46%. This included detection of 83% of the macro-metastasis and 26.3% of the micro-metastasis by FSA. The rest were detected on intensive ultra-staging protocol.  Although they concluded that FSA is an unreliable tool, it could still avert an unnecessary morbid procedure in almost half of the women.

NCCN recommends radical hysterectomy with SLNB or pelvic lymphnode dissection in early cervical cancer. European society guidelines say that if on frozen section analysis, SLN is negative, then a systematic pelvic lymphadenectomy is recommended . While, FIGO still maintains SLNB to be experimental .

Despite all this international evidence regarding SLNB in cervical cancer, prospective Indian data remains sparse, with just one small study. Hence, we propose to conduct this prospective cohort study to validate the SLNB procedure in cervical cancer, its FSA and ultrastaging in our institute, by testing its diagnostic performance and adding to the existing pool of data.

This prospective cohort pilot study aims to evaluate the diagnostic accuracy of the sentinel lymph node (SLN) mapping algorithm combined with ultra-staging in detecting lymph node metastasis in patients with early-stage cervical cancer, using systematic lymphadenectomy with routine histopathological examination (H&E staining) as the gold standard. After obtaining approval from the Institutional Ethics Committee, 20 consecutive eligible patients with clinical and radiological early-stage cervical cancer planned for primary surgery will be recruited following informed consent. All patients will undergo open surgery with indocyanine green (ICG)-guided SLN mapping involving four-quadrant cervical injections. SLN identification will be performed using near-infrared imaging, followed by the excision of mapped SLNs and any suspicious lymph nodes for frozen section analysis (FSA). If metastasis is detected on FSA, radical hysterectomy will be abandoned, and patients will receive definitive chemoradiotherapy; however, they will continue to be included in the study for analysis. If FSA is negative, systematic bilateral pelvic lymphadenectomy and appropriate hysterectomy (Type B/C ± BSO) will be completed. Histopathological evaluation of SLNs will include frozen section, routine H&E staining, and detailed ultra-staging with additional serial sections and immunohistochemistry (IHC) when required. Non-sentinel pelvic lymph nodes will be evaluated with routine H&E staining. Lymph node metastases will be classified as macro-metastasis, micro-metastasis, or isolated tumor cells. The findings of this study will help determine the diagnostic performance of SLN mapping and ultra-staging as a potential alternative to systematic lymphadenectomy in early-stage cervical cancer


 
Close